18F-FES PET/CT's Additional Clinical Value in ER+ BC

To figure out whethetr 18F-FES PET/CT could influence the staging and management of newly diagnosed Oestrogen Receptor-positive Breast Cancer Patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Biyun Wang, MD

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with newly diagnosed immunohistochemical confirmed oestrogen receptor (ER)-positive breast cancer
Patients underwent both 18F-FES PET/CT and 18F-FDG PET/CT in Fudan University Shanghai Cancer Center within 1 week after diagnosis
Patients with available medical history

Exclusion criteria

Patients with incomplete medical history

Treatment and study plan

Primary outcomes

Staging of breast cancer

Time frame: 6 weeks

Deliver questionnaire to phycians to investigate the staging of BC according to AJCC 8 (TNM staging).

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

18F-FES PET/CT Influences the Staging and Management of Newly Diagnosed Oestrogen Receptor-Positive Breast Cancer Patients: A Retrospective Comparative Study With 18F-FDG PET/CT

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Jul 5, 2019
Registry last updated: Jul 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed